PMH39 Cost Effectiveness of A Collaboratieve Care Stepped intervention for Anxiety Disorders in the Primairy Care Setting  by Goorden, M. et al.
per QALY gained. Multiple sensitivity analyses were undertaken to test the robust-
ness of the model including both one-way sensitivity analyses and multivariate
probabilistic sensitivity analyses using Monte Carlo simulations. RESULTS: PP-LAI
treated patients were in remission 249 days and accumulated a total of 0.633 QALYs
at a cost of 89,360 NOK. OLZ-LAI treated patients were in remission 243 days and
accumulated a total of 0.621 QALYs at a cost of 100,888 NOK. The result was that
PP-LAI was the dominant treatment strategy (more effective and less costly). Re-
sults were robust over a wide range of sensitivity analyses tested. The main drivers
of the model included compliance rates and the price of each pharmacotherapy,
with PP-LAI being less costly than OLZ-LAI. CONCLUSIONS: PP-LAI was cost-effec-
tive compared with OLZ-LAI in the treatment of schizophrenia in Norway.
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OBJECTIVES: To use administrative data in a Markov simulation that compares the
cost-effectiveness of depot flupentixol and long-acting risperidone in the treat-
ment of schizophrenia. METHODS: We employed a Markov model to simulate
treatment for schizophrenic patients during 24 cycles with a cycle length of 30
days. The model comprised three non-absorbing states, i.e. inpatient treatment,
outpatient treatment with the patient either being compliant or not, and three
absorbing states, i.e. switching from index medication, death and dropout. Com-
pliance was defined using a refill persistence measure. Treatment costs from the
payer’s perspective, i.e. cost of outpatient, inpatient and pharmaceutical care, and
hospitalization were used as outcomes. Transition probabilities between Markov
states and outcomes for each state were estimated from an administrative dataset
comprising 935 patients who were hospitalized with schizophrenia (ICD-10:F20)
between 2005 and 2008 and who subsequently received depot flupentixol or ris-
peridone. It was adjusted for age, sex, prior hospitalization, prior sick leave, early
retirement, and comorbid conditions according to the Elixhauser score using
multinomial logistic and gamma regression models, respectively. RESULTS: Co-
hort simulation based on 1000 patients on average aged 40.8 years, 55.0% male with
38.0 days of prior annual hospitalization, showed that 102 (266) patients treated
with flupentixol (risperidone) remained in a non-absorbing state after 24 cycles.
Thus switching to other antipsychotics occurred more often with flupentixol. Av-
erage cost of treatment with flupentixol (risperidone) was 544.52 € (1,109.67 €) per
patient and cycle. While patients treated with flupentixol were hospitalized more
often compared to risperidone (5.2% vs. 4.8% per cycle), length of hospitalization
was lower with flupentixol as compared to risperidone (16.11 vs. 16.53 days).
CONCLUSIONS: The effectiveness of depot flupentixol in preventing relapse ap-
pears to be similar to long-acting risperidone. While treatment costs were lower
with flupentixol, switching rates seem to be higher.
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OBJECTIVES: To evaluate the treatment management cost, over 12 weeks, of
asenapine relative to quetiapine, olanzapine, and aripiprazole which are currently
used in Finland and Sweden to treat moderate to severe manic in bipolar I disorder.
METHODS:A cost-minimisation analysis was conducted from a Finnish and Swed-
ish societal perspective. Costs were the only consideration due to similar clinical
efficacy of asenapine demonstrated in active controlled non-inferiority clinical
trial vs olanzapine and through indirect comparisons with quetiapine and aripipra-
zole. Due to significant differences in adverse events and healthcare system costs,
we included management of weight gain, akathesia and insomnia. Patients were
assumed to start treatment as an inpatient for the first month of therapy, and then
followed for two months in an outpatient setting. All direct and indirect resource
use and unit cost estimates were derived from the latest available sources and
literature. No evidence exists suggesting any differences with respect to healthcare
management (e.g. hospitalisation) between treatment strategies. Thus, estimated
resource use and costs applied were assumed the same across treatment strate-
gies. Deterministic sensitivity analyses were conducted to explore uncertainty
around input parameters. RESULTS: The estimated direct cost of treatment and of
the management of adverse events related to treating adults with bipolar I disorder
suffering a manic or mixed episode for 12 weeks with asenapine monotherapy for
Finland and Sweden were respectively: €421 and €670 (SEK 6,044) compared to €502
and €1139 (SEK 10,257; aripiprazole), €141 and €827 (SEK 7,453; quetiapine), and €344
and €957 (SEK 8,616; olanzapine). CONCLUSIONS: Asenapine has been shown to be
cost saving relative to aripiprazole in Finland and to quetiapine, olanzapine, and
aripiprazole in Sweden at the short-term endpoint of 12 weeks. The estimated
treatment cost represented less than 6% of the overall burden of bipolar disorder
from societal perspective.
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OBJECTIVES: prevalence of heroin addiction among Italian population aged 15-64
is 0.8%. Three different drugs are currently available for treating heroin addiction:
methadone, buprenorphine and buprenorphine/naloxone. A monocenter, retro-
spective, one-year follow-up cost-utility analysis (CUA) was performed to compare
buprenorphine/naloxone (211 patients) vs buprenorphine (214 patients) and meth-
adone (512 patients) for heroin addiction detoxification at Department of Addic-
tions, Local Health Authority of Varese, Italy. METHODS: CUA adopted the Depart-
ment of Addictions viewpoint. Clinical, economic and utility data were obtained
from the database of the Department of Addictions and literature. Drugs, bottles for
methadone take-home doses, health care and social services were identified,
quantified and valued in Euro (€) 2009. One-way and probabilistic sensitivity anal-
yses (SAs) were performed. RESULTS: 87.8% of patients are male. Mean (standard
deviation) patients’ age is 37.97.2 years, whereas patients’ first contact with her-
oin dates back to 16.78.5 years. Neither heterogeneity nor sample selection bias
have been detected among treatment groups. Buprenorphine and methadone are
the most and the least costly options (€3257.24 and €2219.47 per patient, respec-
tively). Buprenorphine/naloxone costs €2541.05 per patient. During one-year fol-
low-up patients accrue 0.573 (methadone), 0.599 (buprenorphine) and 0.602 (bu-
prenorphine/naloxone) Quality-Adjusted Life Years (QALYs). Buprenorphine is
strongly dominated by buprenorphine/naloxone and hence ruled out from the base
case CUA. The incremental cost-utility ratio for buprenorphine/naloxone vs meth-
adone is €11,195.12. SAs confirm the robustness of the base case findings. Cost-
Effectiveness Acceptability Curve shows that the probability for buprenorphine/
naloxone to be cost-effective equals 0.58, 0.61 and 0.62 against €25,000, €40,000 and
€50,000 threshold-values, respectively. Cost-Effectiveness Acceptability Frontier
highlights that buprenorphine/naloxone is the optimal alternative from a thresh-
old-value of €11,391.14. CONCLUSIONS: Buprenorphine/naloxone seems advisable
even from an economic point of view, since its incremental cost-utility ratio falls
well within the usual acceptability standards for incremental QALY saved (€25,000-
40,000; €50,000).
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OBJECTIVES: To evaluate the cost-effectiveness of a collaborative stepped care
intervention (CSC) for panic disorder and generalised anxiety disorder in primary
care compared to care as usual (CAU).METHODS:A two armed cluster randomised
controlled trial, 43 primary care practices participated in the study. Patients se-
lected by their general practitioner and patients selected from files screening pos-
itive on an anxiety screener, had a MINI International Neuropsychiatric Interview
to classify DSM-IV disorders. Eventually, 180 patients with a diagnosis of panic
disorder or generalised anxiety disorder were included in the study (114 collabor-
ative stepped care, 66 care as usual). Baseline measurements and follow up mea-
sures (3, 6, 9 and 12 months) were assessed using questionnaires. We applied the
TiC-P and the EQ-5D respectively assessing the health care utilization, production
losses and general health related quality of life. The incremental analysis indicated
costs per QALY. RESULTS: The average annual direct medical costs in the collab-
orative stepped care group were 1987 Euro (sd 2027), compared to 1645 Euro (sd
1844) in the care as usual group. The average quality of life years (QALY’s) gained
was higher in the collaborative stepped care group compared to the care as usual
group, 0.08 QALY. The incremental cost utility was about 4100 euro per QALY.
Including both the direct medical costs and productivity costs the collaborative
stepped care group dominated CAU. CONCLUSIONS: The study showed that CSC is
a cost effective intervention for anxiety disorder in the primary care setting and
even dominant including productivity costs.
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OBJECTIVES: Despite the availability of numerous antidepressants, persistence
with treatment is poor and adverse events are a key factor. Agomelatine is a new
chemical entity for the treatment of major depressive disorders (MDD) with a pla-
cebo-like side effect profile resulting in a statistically significantly higher propor-
tion of patients continuing treatment compared with venlafaxine. The objective of
this study was to conduct a cost-utility analysis of agomelatine compared with
venlafaxine from an Australian healthcare perspective to inform reimbursement
decision making by the Pharmaceutical Benefits Advisory Committee (PBAC).
METHODS: An Excel-based Markov model was developed with four states ‘de-
pressed’, ‘remission’, ‘well’ and ‘death’ with a three year time-horizon. Agomela-
tine and venlafaxine were assumed to be equally effective in the treatment of
depressive symptoms but to differ in discontinuation rates, requirement for down
titration and costs. Patients enter the model in the ‘depressed’ state and can prog-
ress to ‘remission’ where they may relapse and re-enter ‘depressed’ or move to the
‘well’ state (after spending six months in ‘remission’). Patients in the ‘depressed’ or
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